Quizartinib

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Acute Myeloid Leukemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (3)
CN
  • Newly diagnosed FLT3-ITD positive AML with chemotherapy and maintenance monotherapy
Product first approved 20261stoncology.com
EU
  • Newly diagnosed FLT3-ITD positive AML, with chemotherapy then single-agent maintenance
Product first approved 2023EMA
JP
  • Relapsed/refractory FLT3-ITD AML (newly diagnosed indication added 2023-05-25)
Product first approved 2019prnewswire.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (6)
Acute Myeloid Leukemia
NCT07948122 · University Hospital, Toulouse
2027-01-04 – 2037-12-31 · Acute Myeloid Leukemia
What this study did
NCT06578247 · Daiichi Sankyo
2024-11-19 – 2030-06-26 · Leukemia
What this study did
NCT07478991 · PETHEMA Foundation
2026-07-02 – 2030-04 · Acute Myeloid Leukemia, Adult
What this study did
NCT04676243 · University Hospital Heidelberg
2022-05 – 2025-12 · Acute Myeloid Leukemia
What this study did
Phase 2 (12)
Acute Myeloid Leukemia
NCT06824168 · Daiichi Sankyo
2025-07-18 – 2032-07-14 · Acute Myeloid Leukemia, Leukemia
What this study did
NCT06262438 · Princess Maxima Center for Pediatric Oncology
2024-02-06 – 2032-06 · Acute Myeloid Leukemia in Children
What this study did
NCT05564390 · National Cancer Institute (NCI)
2024-06-18 – 2029-05-15 · Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
What this study did
NCT07548710 · Ruijin Hospital
2026-05-01 – 2028-12-21 · Acute Myeloid Leukemia
What this study did
NCT03989713 · Prof. Dr. Richard F Schlenk
2020-07-17 – 2022-09-11 · AML According to WHO 2016 Classification (Except Acute Promyelocytic Leukemia) AND (Refractory to Induction Therapy OR Relapsed After First Line Treatment)
What this study did
NCT03135054 · The University of Hong Kong
2017-10-01 – 2021-10-01 · AML, FLT3-ITD Mutation
What this study did
NCT04209725 · SCRI Development Innovations, LLC
2020-06-03 – 2021-04-20 · Leukemia, Myeloid, Acute
What this study did
NCT02984995 · Daiichi Sankyo Co., Ltd.
2016-12-08 – 2018-09-14 · Leukemia, Myeloid, Acute
What this study did
NCT01565668 · Daiichi Sankyo
2012-04 – 2015-03 · Leukemia, Myeloid, Acute
What this study did
NCT00989261 · Daiichi Sankyo
2009-11 – 2014-12-31 · Acute Myeloid Leukemia
What this study did
Phase 1/2 (10)
Acute Myeloid Leukemia
NCT03661307 · M.D. Anderson Cancer Center
2018-10-31 – 2028-01-01 · Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia
What this study did
NCT04047641 · M.D. Anderson Cancer Center
2019-10-22 – 2027-12-31 · Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent High Risk Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory High Risk Myelodysplastic Syndrome
What this study did
NCT04128748 · M.D. Anderson Cancer Center
2020-05-27 – 2027-12-31 · Acute Myeloid Leukemia, Blasts More Than 10 Percent of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
What this study did
NCT03793478 · Daiichi Sankyo
2018-08-15 – 2027-05-01 · Acute Myeloid Leukemia
What this study did
NCT03735875 · M.D. Anderson Cancer Center
2019-01-25 – 2023-07-26 · Acute Myeloid Leukemia With FLT3/ITD Mutation, Recurrent Acute Myeloid Leukemia, Refractory Acute Leukemia
What this study did
NCT01892371 · M.D. Anderson Cancer Center
2013-11-12 – 2023-02-07 · FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome
What this study did
Other / comorbidity
NCT04493138 · M.D. Anderson Cancer Center
2020-07-21 – 2027-12-31 · Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Myeloproliferative Neoplasm
What this study did
Phase 1 (18)
Acute Myeloid Leukemia
NCT06769490 · M.D. Anderson Cancer Center
2025-07-10 – 2030-09-15 · Acute Myeloid Leukemia
What this study did
NCT05735184 · Kura Oncology, Inc.
2023-07-18 – 2030-04 · Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML, AML With Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma, Nucleophosmin 1-mutated Acute Myeloid Leukemia
What this study did
NCT03723681 · Daiichi Sankyo Co., Ltd.
2018-11-05 – 2022-03-03 · Acute Myeloid Leukemia (AML)
What this study did
NCT03552029 · Daiichi Sankyo
2018-12-12 – 2021-04-01 · Acute Myeloid Leukemia
What this study did
NCT02675478 · Daiichi Sankyo Co., Ltd.
2016-02 – 2018-11-13 · Relapsed AML, Refractory AML
What this study did
NCT02834390 · Daiichi Sankyo Co., Ltd.
2016-08-12 – 2017-10-19 · Acute Myeloid Leukemia
What this study did
NCT01468467 · Daiichi Sankyo
2012-04 – 2015-03 · Leukemia, Myeloid, Acute
What this study did
NCT01390337 · Daiichi Sankyo
2011-10 – 2015-02 · Leukemia, Myeloid, Acute
What this study did
NCT01411267 · Therapeutic Advances in Childhood Leukemia Consortium
2011-09-01 – 2013-09-12 · Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood
What this study did
NCT00462761 · Daiichi Sankyo
2007-01 – 2009-12 · Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndrome, AML, MDS
What this study did
Other / comorbidity
NCT06740799 · Daiichi Sankyo
2024-09-30 – 2026-10-31 · Hepatic Impairment
What this study did
NCT06772246 · Daiichi Sankyo
2024-10-24 – 2025-06-12 · Healthy Subjects
What this study did
NCT06740825 · Daiichi Sankyo
2024-10-29 – 2024-12-09 · Healthy Subjects
What this study did
NCT04473664 · Daiichi Sankyo
2020-09-22 – 2021-07-22 · Hepatic Impairment, Moderate Impaired Hepatic Function
What this study did
NCT04796831 · Daiichi Sankyo
2021-04-26 – 2021-06-11 · Healthy Subjects
What this study did
NCT04459585 · Daiichi Sankyo Co., Ltd.
2020-08-28 – 2020-10-20 · Healthy Subjects, Drug-drug Interaction, Pharmacokinetics, Quizartinib
What this study did
NCT04459598 · Daiichi Sankyo Co., Ltd.
2020-08-19 – 2020-10-14 · Healthy Subjects, Drug-drug Interaction, Pharmacokinetics, Quizartinib
What this study did
NCT01049893 · Daiichi Sankyo
2010-01 – 2011-11 · Solid Tumors
What this study did
Phase 4 (1)
Acute Myeloid Leukemia
NCT07949344 · Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
2026-12-01 – 2030-06-30 · Acute Myeloid Leukemia
What this study did

Competitive landscape

5 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Acute Myeloid Leukemia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Quizartinib: this drugApprovedSmall moleculeFLT3Reliable signal
NCT02668653: Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment): Quizartinib 31.9 months vs Placebo 15.1 months (95% CI 13.2 to 26.2)
Azacitidine (Onureg)ApprovedSmall moleculeDNMT1 (DNA methyltransferase 1)Weak signal
NCT01757535: QUAZAR AML-001 (n=472), primary endpoint overall survival: median 24.7 months (95% CI 18.7 to 30.5) with oral azacitidine vs 14.8 months (95% CI 11.7 to 17.6) with placebo; HR 0.69 (95% CI 0.55 to 0.86), stratified log-rank p=0.0009 (CT.gov posted results).
Decitabine / Cedazuridine (Inqovi)ApprovedSmall moleculeDecitabine/cedazuridine fixed combination (DNMT + CDA inhibition)Partial signalFeatured results are non-efficacy only in this race
Enasidenib (Idhifa)ApprovedSmall moleculeIDH2Partial signal
NCT02577406: Overall Survival (OS) (From randomization to death due to any cause (up to approximately 49 months)): AG-221 6.5 Months (95% CI 5.5 to 9.5) missed
Gemtuzumab OzogamicinApprovedAntibody–drug conjugateCD33Partial signal
NCT00893399: Short-term event-free survival at 6-month follow-up: 53% standard vs 58% gemtuzumab ozogamicin (HR 0·83; p=0·10); 2-year overall survival: 69% vs 73% (0·90; p=0·43) missed
NCT00372593: Two primaries at 3 years: event-free survival 53.1% with gemtuzumab ozogamicin plus chemotherapy vs 46.9% with chemotherapy alone, HR 0.83 (95% CI 0.70 to 0.99), P = .04 (met); overall survival 69.4% vs 65.4%, HR 0.91 (95% CI 0.74 to 1.13), P = .39 (missed); 1,022 evaluable patients.
GilteritinibApprovedSmall moleculeFLT3Partial signal
NCT02752035: Overall Survival (OS) (From the date of randomization until the date of death from any cause ( maximum duration up to 79 months)): Randomized Cohort: Gilteritinib + AZA 9.82 months (95% CI 8.11 to 13.17) | Randomized Cohort: Gilteritinib 5.24 months (95% CI 2.46 to 15.18) vs Randomized Cohort: AZA 9.23 months (95% CI 4.34 to 12.55) missed
GlasdegibApprovedSmall moleculeHedgehog Pathway InhibitorPartial signalNo reviewed efficacy summary in this indication
Ivosidenib (Tibsovo)ApprovedSmall moleculeMutant IDH1Reliable signal
NCT03173248: Event-free survival HR 0.33 (95% CI 0.16 to 0.69), one-sided stratified log-rank p = 0.0011 (registry analysis)
Midostaurin (Rydapt)ApprovedSmall moleculeFLT3;KIT;PKC;PDGFRWeak signal
NCT03512197: Event Free Survival (EFS) (From date of Randomization up to approx. 30 months): Midostaurin + Chemotherapy 5.98 Months (95% CI 2.33 to 8.97) vs Placebo + Chemotherapy 5.88 Months (95% CI 3.65 to 7.52) missed
NCT00651261: Overall survival, chemotherapy + midostaurin vs chemotherapy + placebo: median 74.7 vs 25.6 months, hazard ratio 0.78 (95% CI 0.63 to 0.96), one-sided p=0.009 (n=360 and 357) (CT.gov posted results).
OlutasidenibApprovedSmall moleculeMutant IDH1Weak signalFeatured results are safety only in this race
Orca-T (TREGZI)ApprovedCell therapyAllogeneic engineered T-cell immunotherapyPartial signal
NCT05316701: Event-free at 12 Months for Moderate or Severe Chronic Graft-versus-Host-Disease-free Survival (cGFS) Per Endpoint Adjudication Committee (EAC) (Day 0 through 730 days after transplantation): Orca-T 78% (95% CI 65 to 86.6) vs Standard of Care 38.4% (95% CI 26.2 to 50.5)
RevumenibApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
Sargramostim (Leukine)ApprovedProtein / enzyme therapeuticGM-CSF receptornot yet gradedNo reviewed efficacy summary in this indication
Tretinoin (Vesanoid)
ApprovedUS marketing discontinued
Small moleculeRARA (retinoic acid receptor alpha); degrades the PML-RARA fusion oncoprotein in APLnot yet graded
NCT00003934: Complete remission (response rate): 90% in each arm. Event-free survival at 3 years (a co-registered primary endpoint): 80% with arsenic trioxide (As2O3) consolidation vs 63% with standard consolidation alone (P<.0001). phase 3 result · pivotal pending
VenetoclaxApprovedSmall moleculeBCL-2Reliable signal
NCT03069352: Overall Survival (OS) (From randomization until the primary analysis cut-off date of February 15 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.): Venetoclax + Low Dose Cytarabine (LDAC) 7.2 months (95% CI 5.6 to 10.1) | Placebo + Low Dose Cytarabine (LDAC) 4.1 months (95% CI 3.1 to 8.8) missed
VyxeosApprovedSmall moleculeDNA synthesis (cytarabine, antimetabolite) / Topoisomerase IIPartial signal
NCT01696084: Overall survival, Vyxeos (CPX-351) vs 7+3 in patients 60 to 75 years with newly diagnosed t-AML or AML-MRC: median 9.6 months (95% CI 6.6 to 11.9) vs 5.9 months (95% CI 5.0 to 7.8); HR 0.69 (95% CI 0.52 to 0.90), two-sided p=0.005. n=153 vs 156 (FDA label, Study 1).
ZiftomenibApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
131I-ApamistamabPhase 3Monoclonal antibodyCD45Partial signal
NCT02665065: SIERRA (NCT02665065), primary endpoint durable complete remission (dCR) at 6 months: Iomab-B 22% (13/59) vs control 0%; p<0.0001
Arsenic Trioxide (QTX-2101)Phase 3Small moleculePML-RARA fusion oncoproteinnot yet gradedNo reviewed efficacy summary in this indication
Arsenic Trioxide (SDK001)Phase 3Small moleculePML-RARA fusion oncoproteinPartial signalNo reviewed efficacy summary in this indication
AzacitidinePhase 3Small moleculeDNMT1 (DNA methyltransferase 1)Partial signal
NCT00887068: Relapse-free survival: median 2.07 years with azacitidine maintenance vs 1.28 years with observation (P=.43); multivariate hazard ratio 0.73 (95% CI 0.49 to 1.1; P=.14) (Oran et al., Blood Adv 2020). missed
BleximenibPhase 3Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
Clifutinib BesylatePhase 3Small moleculeFLT3not yet gradedNo reviewed efficacy summary in this indication
CrenolanibPhase 3Small moleculeFLT3 (including D835/ITD mutants), also PDGFR-alpha/betaReliable signal
NCT03250338: EFS: 3.4 vs. 0.0 months crenolanib plus chemotherapy vs chemotherapy alone (HR = 0.64, p = 0.0145)
Galinpepimut-SPhase 3VaccineWT1 (Wilms Tumor-1 protein)Weak signal
NCT01266083: Overall Survival (3 years): Galinpepimut-S + Montanide + GM-CSF 47%
LisaftoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MesutoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MocravimodPhase 3Small moleculeSphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)not yet gradedNo reviewed efficacy summary in this indication
RuserontinibPhase 3Small moleculeFLT3 / EGFR / ABL (also Fyn, Hck, Lck, Lyn, Ret, Yes)Partial signalNo reviewed efficacy summary in this indication
XY0206Phase 3Small moleculeFLT3not yet gradedNo reviewed efficacy summary in this indication
AnnamycinPhase 2/3Small moleculeTopoisomerase II (TOP2)not yet gradedNo reviewed efficacy summary in this indication
BL-M11D1Phase 2/3Antibody–drug conjugateCD33not yet gradedNo reviewed efficacy summary in this indication
Pivekimab Sunirine (Decnupaz)Phase 2/3Antibody–drug conjugateCD123not yet gradedNo reviewed efficacy summary in this indication
CusatuzumabPhase 2Monoclonal antibodyCD70Weak signal
NCT03030612: Objective response in 19/38 patients (8/26 in the phase II portion); complete remission in 14/38
Lintuzumab-Ac225Phase 2RadiopharmaceuticalCD33Weak signalNo reviewed efficacy summary in this indication
PegargiminasePhase 2Protein / enzyme therapeuticArginine-depleting pegylated arginine deiminaseWeak signal
NCT01910012: Among 21 evaluable patients (of 43 enrolled): complete response 2/21 (9.5%), stable disease 7/21 (33.3%), disease control rate 42.9%; CR duration 7.5 and 8.8 months
PrexigebersenPhase 2RNA / oligonucleotideGRB2 (growth factor receptor-bound protein 2) mRNAWeak signalFeatured results are safety only in this race
RomaciclibPhase 2Small moleculeCDK8 / CDK19Weak signal
NCT04021368: RVU120 (CDK8/19 inhibitor) phase 1 dose escalation, AML/HR-MDS (protocol CLI120-001 = NCT04021368): no DLTs, SAEs unrelated to drug; among the first 5 patients treated, 1 CR and 1 erythroid response
Sonrotoclax (Beqalzi)Phase 2Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
TagraxofuspPhase 2Protein / enzyme therapeuticCD123Weak signalNo reviewed efficacy summary in this indication
VididencelPhase 2VaccineAllogeneic dendritic cell vaccineWeak signal
NCT03697707: MRD response in 7/20 (35%) patients (5/20 converted MRD-negative, 2/20 with >=10-fold MRD reduction). Long-term follow-up (ASH 2025, median 55 months): 13 of 20 patients alive, 8 past 5-year follow-up, estimated 5-year overall survival 63% (sponsor-reported).
AB8939Phase 1/2Small moleculeTubulinnot yet gradedNo reviewed efficacy summary in this indication
ABD-3001Phase 1/2Small moleculeALDH (aldehyde dehydrogenase family, including ALDH1A1/ALDH3A1)not yet gradedNo reviewed efficacy summary in this indication
AlrizomadlinPhase 1/2Small moleculeMDM2Weak signalNo reviewed efficacy summary in this indication
ARD103Phase 1/2Cell therapyCLL-1 (CLEC12A)not yet gradedNo reviewed efficacy summary in this indication
AZD3632Phase 1/2Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
BexmarilimabPhase 1/2Monoclonal antibodyClever-1not yet gradedNo reviewed efficacy summary in this indication
BG1805Phase 1/2Cell therapyCLL-1 (CLEC12A)not yet gradedNo reviewed efficacy summary in this indication
BSB-1001Phase 1/2Cell therapyHA-1 (minor histocompatibility antigen)not yet gradedNo reviewed efficacy summary in this indication
CART84Phase 1/2Cell therapyCD84not yet gradedNo reviewed efficacy summary in this indication
CCTx-001Phase 1/2Cell therapyIL-1RAPnot yet gradedNo reviewed efficacy summary in this indication
CD123 Targeted CAR-NK CellsPhase 1/2Cell therapyCD123Weak signalNo reviewed efficacy summary in this indication
CD123 / CD33 CARTPhase 1/2Cell therapyCD123 / CD33not yet gradedNo reviewed efficacy summary in this indication
CLN-049Phase 1/2Multispecific antibodyFLT3, CD3not yet gradedNo reviewed efficacy summary in this indication
Debio 1562MPhase 1/2Antibody–drug conjugateCD37not yet gradedNo reviewed efficacy summary in this indication
EmavusertibPhase 1/2Small moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication
EnzomenibPhase 1/2Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
LigufalimabPhase 1/2Monoclonal antibodyCD47not yet gradedNo reviewed efficacy summary in this indication
MobinitinibPhase 1/2Small moleculeFLT3 / Aurora kinase A and Bnot yet gradedNo reviewed efficacy summary in this indication
MRX-2843Phase 1/2Small moleculeFlt3/MerTKWeak signalNo reviewed efficacy summary in this indication
OcifisertibPhase 1/2Small moleculePLK4 (Polo-like kinase 4)Weak signalFeatured results are safety only in this race
OlverembatinibPhase 1/2Small moleculeBCR-ABL (also AKT, c-Kit, ERK)not yet gradedNo reviewed efficacy summary in this indication
OrcaGraft (Orca-Q)Phase 1/2Cell therapyTreg-enriched allogeneic haematopoietic stem cell graftnot yet gradedNo reviewed efficacy summary in this indication
RogocekibPhase 1/2Small moleculeCLK (CDC-like kinase family)not yet gradedNo reviewed efficacy summary in this indication
Anti-CI135 CAR-TPhase 1Cell therapyFLT3not yet gradedNo reviewed efficacy summary in this indication
BMF-500Discontinued—FLT3not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 65 furthest-along competitors are listed; 65 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(16 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Quizartinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (6)
May 2027 (2)
Phase 1/2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-05-01 · NCT03793478 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-05-31 · NCT07548710 · CT.gov ↗
What to watch
December 2027 (4)
Phase 1/2Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Chronic Myelomonocytic Leukemia …Active not recruiting
Est. primary completion 2027-12-31 · NCT04493138 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-12-31 · NCT04047641 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-12-31 · NCT04128748 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07862517 · CT.gov ↗
What to watch
2028 (4)
January 2028 (1)
Phase 1/2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2028-01-01 · NCT03661307 · CT.gov ↗
What to watch
June 2028 (2)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-06 · NCT06262438 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-06-06 · NCT06824168 · CT.gov ↗
What to watch
September 2028 (1)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-09-15 · NCT06769490 · CT.gov ↗
What to watch
2029 (1)
May 2029 (1)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-05-15 · NCT05564390 · CT.gov ↗
What to watch
2030 (4)
April 2030 (2)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2030-04 · NCT05735184 · CT.gov ↗
What to watch
Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2030-04 · NCT07478991 · CT.gov ↗
What to watch
June 2030 (2)
Phase 3Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2030-06-26 · NCT06578247 · CT.gov ↗
What to watch
Phase 4Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2030-06-30 · NCT07949344 · CT.gov ↗
What to watch
2035 (1)
December 2035 (1)
Phase 3Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2035-12-31 · NCT07948122 · CT.gov ↗
What to watch

See the full readout calendar ↗